MPR delivers practical, up-to-date drug information to healthcare professionals. Using the expertise gained from 25 years of providing point-of-care drug tools, MPR has now created a drug review course exclusively for See below for a list of each quarter's courses. Click here to visit MPR's website.

Latest Courses

Clinical Review

New Drug Review from MPR (April 2014)

1.00 Credits
Clinical Review

New Drug Review from MPR (October 2013)

1.00 Credits

Archived CME/CE Courses


MPR Drug News

Pompe Disease Drug Now Approved for All Ages

The FDA announced the approval of Lumizyme (alglucosidase alfa; Genzyme) for the treatment of all patients with infantile-onset Pompe disease.

New Oral Diabetes Drug Approved

The FDA announced the approval of Jardiance (empagliflozin; Boehringer Ingelheim) tablets as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

FDA Seeks Diagnostic Test Regulation

The FDA has issued a final guidance on the development, review, and approval or clearance of companion diagnostics and is intending to publish a proposed risk-based oversight framework for laboratory developed tests (LDTs).

New Smaller ChloraPrep Applicator Launched

CareFusion announced the launch of its ChloraPrep 1mL applicator, the latest addition to the ChloraPrep line.

Striverdi Respimat Inhaler Approved for COPD

The FDA has approved Striverdi Respimat (olodaterol; Boehringer Ingelheim) inhalation spray for the treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema with airflow obstruction.